Innocan Pharma CorporationINNO.CN
Key ratios
FCF / Sales
-6.6%TTM
2025
1.8%2024
-5.4%2023
-28.9%
Net margin
-4.1%TTM
2025
-4.2%2024
-6.2%2023
-34.4%
Revenue growth
-18.4%TTM
2025
-9.6%2024
115.6%2023
433.7%
Recent news
VALITIC™ Launches Direct-to-Consumer Website, Laying Groundwork for U.S. Holiday Campaign
VALITIC™ Featured by BuzzFeed for "Magical Results," Further Strengthening Consumer Brand Momentum
VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
Innocan Pharma Announces First Tranche Closing of Private Placement of Units
Innocan Pharma Announces Private Placement of Units
Innocan Pharma Announces Second Quarter Fiscal Year 2026 Results
Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth
Track INNO.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer